Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis
- PMID: 27416043
- PMCID: PMC4956520
- DOI: 10.1097/MIB.0000000000000823
Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis
Abstract
Background: 5-aminosalicylic acid (5-ASA) is a classic anti-inflammatory drug for the treatment of ulcerative colitis. N-acetyltransferase (NAT) enzymes convert 5-ASA to its metabolite N-acetyl-5-ASA, and it is unresolved whether 5-ASA or N-acetyl-5-ASA is the effective therapeutic molecule. We previously demonstrated that colonic production of N-acetyl-5-ASA (NAT activity) is decreased in dextran sulfate sodium-induced colitis. Our hypothesis is that 5-ASA is the therapeutic molecule to improve colitis, with the corollary that altered NAT activity affects drug efficacy. Since varying clinical effectiveness of 5-ASA has been reported, we also ask if NAT activity varies with inflammation in pediatric or adult patients.
Methods: Acute colonic inflammation was induced in C57BL/6 NAT wild-type (WT) or knockout mice, using 3.5% dextran sulfate sodium (w/v) concurrent with 5-ASA treatment. Adult and pediatric rectosigmoid biopsies were collected from control or patients with ulcerative colitis. Tissue was analyzed for NAT and myeloperoxidase activity.
Results: Dextran sulfate sodium-induced colitis was of similar severity in both NAT WT and knockout mice, and NAT activity was significantly decreased in NAT WT mice. In the setting of colitis, 5-ASA significantly restored colon length and decreased myeloperoxidase activity in NAT knockout but not in WT mice. Myeloperoxidase activity negatively correlated with NAT activity in pediatric patients, but correlation was not observed in adult patients.
Conclusions: Inflammation decreases NAT activity in the colon of mice and human pediatric patients. Decreased NAT activity enhances the therapeutic effect of 5-ASA in mice. A NAT activity assay could be useful to help predict the efficacy of 5-ASA therapy.
Figures






Similar articles
-
Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.Am J Physiol Gastrointest Liver Physiol. 2014 Jun 1;306(11):G1002-10. doi: 10.1152/ajpgi.00389.2013. Epub 2014 Apr 17. Am J Physiol Gastrointest Liver Physiol. 2014. PMID: 24742986 Free PMC article.
-
Addition of Berberine to 5-Aminosalicylic Acid for Treatment of Dextran Sulfate Sodium-Induced Chronic Colitis in C57BL/6 Mice.PLoS One. 2015 Dec 7;10(12):e0144101. doi: 10.1371/journal.pone.0144101. eCollection 2015. PLoS One. 2015. PMID: 26642326 Free PMC article.
-
Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.Aliment Pharmacol Ther. 2019 May;49(10):1301-1313. doi: 10.1111/apt.15227. Epub 2019 Mar 20. Aliment Pharmacol Ther. 2019. PMID: 30895635 Free PMC article.
-
5-Aminosalicylic acid, a specific drug for ulcerative colitis.Scand J Gastroenterol. 2015 Aug;50(8):933-41. doi: 10.3109/00365521.2015.1018937. Epub 2015 Mar 2. Scand J Gastroenterol. 2015. PMID: 25733192 Review.
-
Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.Aliment Pharmacol Ther. 2011 May;33(9):996-1009. doi: 10.1111/j.1365-2036.2011.04619.x. Epub 2011 Mar 8. Aliment Pharmacol Ther. 2011. PMID: 21385194 Review.
Cited by
-
Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth.Antibiotics (Basel). 2023 Jan 28;12(2):263. doi: 10.3390/antibiotics12020263. Antibiotics (Basel). 2023. PMID: 36830173 Free PMC article. Review.
-
Genetic and epigenetic mechanisms in the development of congenital heart diseases.World J Pediatr Surg. 2021 Apr 29;4(2):e000196. doi: 10.1136/wjps-2020-000196. eCollection 2021. World J Pediatr Surg. 2021. PMID: 36474778 Free PMC article. Review.
-
Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study.J Clin Med. 2023 Jul 20;12(14):4797. doi: 10.3390/jcm12144797. J Clin Med. 2023. PMID: 37510911 Free PMC article.
-
Cytosolic Phospholipase A2 Is Required for Fexofenadine's Therapeutic Effects against Inflammatory Bowel Disease in Mice.Int J Mol Sci. 2021 Oct 15;22(20):11155. doi: 10.3390/ijms222011155. Int J Mol Sci. 2021. PMID: 34681815 Free PMC article.
-
Protective effect of (E)-(2,4-dihydroxy)-α-aminocinnamic acid, a hydroxy cinnamic acid derivative, in an ulcerative colitis model induced by TNBS.Biosci Rep. 2024 Oct 30;44(10):BSR20240797. doi: 10.1042/BSR20240797. Biosci Rep. 2024. PMID: 39268608 Free PMC article.
References
-
- Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999;274:26448–26453. - PubMed
-
- Galvez J, Garrido M, Rodriguez-Cabezas ME, et al. The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production. Inflamm Bowel Dis. 2003;9:363–371. - PubMed
-
- Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988;33:6S–15S. - PubMed
-
- Horvath K, Varga C, Berko A, et al. The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. Eur J Pharmacol. 2008;581:315–323. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials